Pharming Group
PHAR
3 hedge funds and large institutions have $296K invested in Pharming Group in 2023 Q3 according to their latest regulatory filings, with 2 funds opening new positions, increasing their positions, reducing their positions, and 0 closing their positions.
50% more funds holding
Funds holding: 2 → 3 (+1)
2% more capital invested
Capital invested by funds: $291K → $296K (+$4.82K)
0% more ownership
Funds ownership: 0% → 0% (+0%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCI
Brinker Capital Investments
Berwyn,
Pennsylvania
|
+$146K |
| 2 |
OPS
Orion Portfolio Solutions
Omaha,
Nebraska
|
+$146K |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
BCI
1
Brinker Capital Investments
Berwyn,
Pennsylvania
| $134K | +$146K | +11,715 | New |
|
|
OPS
2
Orion Portfolio Solutions
Omaha,
Nebraska
| $134K | +$146K | +11,715 | New |
|
3
Morgan Stanley
New York
| $28.5K | – | – | – |
|
PHAR Hedge Fund Activity: Q3 2023 in Review
3 of the 6,302 institutional investors tracked by Wall St. Rank reported a position in Pharming Group (PHAR) for Q3 2023, worth a combined $296K — up 1.7% from $291K a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new PHAR positions and 0 closed out — a net gain of 2 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Brinker Capital Investments, opening a new position worth an estimated $146K.
- 3 institutional investors held Pharming Group (PHAR) as of Q3 2023, up from 2 in Q2 2023.
- Funds reported $296K of Pharming Group stock for Q3 2023, up 1.7% quarter-over-quarter.
- 2 funds opened new Pharming Group positions in Q3 2023 and 0 closed out, a net change of +2 holders.
- The largest Pharming Group buyer in Q3 2023 was Brinker Capital Investments, an estimated $146K added.
Based on aggregated 13F filings for Q3 2023.